autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02051257)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06447987 | Phase 1 | Dec 15, 2024 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04484012 | Phase 2 | Jan 15, 2021 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03389230 | Phase 1 | Aug 14, 2018 | City of Hope National Medical Center, Fortress Biotech |
| NCT02051257 | Phase 1 | May 1, 2014 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 4 | 4 | 2 | 2014 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2014 |
| Fortress Biotech | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1